The PROPEL study compared the safety and efficacy of ADYNOVATE® [Antihemophilic Factor [Recombinant], PEGylated] following pharmacokinetic ...
Wednesday, 6 February 2019
Takeda Announces Results from First-of-Its-Kind Phase IIIb/IV Trial PROPEL – a Randomized PK-Guided Prophylaxis Study Evaluating Higher Factor VIII Levels in Hemophilia A– at EAHAD 2019 - Business Wire
Takeda Announces Results from First-of-Its-Kind Phase IIIb/IV Trial PROPEL – a Randomized PK-Guided Prophylaxis Study Evaluating Higher Factor VIII Levels in Hemophilia A– at EAHAD 2019 Business Wire
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment